The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy faces challenges with patient relapse due to limited target options.
• The transferrin receptor (TfR) is highly expressed on proliferating tumor cells, presenting a potential alternative target.
• Developing novel CAR T-cell targets is crucial for improving therapeutic efficacy and overcoming resistance.

Purpose of the Study:

• To investigate the efficacy and challenges of targeting the transferrin receptor (TfR) using CAR T-cell therapy.
• To generate and evaluate TfR-specific CAR T cells for treating hematological malignancies.

Main Methods:

• Generation of a TfR-specific CAR construct.
• Development of TfR-CAR-modified T cells.
• Assessment of TfR-CAR T cells against TfR-positive hematological cancer cell lines in vitro and in vivo.

Main Results:

• TfR-CAR T cells demonstrated potent killing activity against multiple TfR-positive hematological malignant cell lines in vitro.
• TfR-CAR T cells were effective in eradicating T-cell acute lymphoblastic leukemia (T-ALL) cells in vivo.
• The transferrin receptor (TfR) shows potential as a broadly applicable target across various hematological tumors.

Conclusions:

• Transferrin receptor (TfR) serves as a promising universal target for enhancing CAR T-cell therapy.
• TfR-CAR T cells offer a potential alternative therapeutic strategy for hematological malignancies.
• Further research is warranted to advance TfR-CAR T cells as a clinical product.